{Reference Type}: Practice Guideline
{Title}: SFE-AFCE-SFMN 2022 consensus on the management of thyroid nodules: Surgical treatment.
{Author}: Menegaux F;Baud G;Chereau N;Christou N;Deguelte S;Frey S;Guérin C;Marciniak C;Paladino NC;Brunaud L;Caiazzo R;Donatini G;Gaujoux S;Goudet P;Hartl D;Lifante JC;Mathonnet M;Mirallié E;Najah H;Sebag F;Trésallet C;Pattou F;
{Journal}: Ann Endocrinol (Paris)
{Volume}: 83
{Issue}: 6
{Year}: Dec 2022
{Factor}: 3.117
{DOI}: 10.1016/j.ando.2022.10.012
{Abstract}: The SFE-AFCE-SFMN 2022 consensus deals with the management of thyroid nodules, a condition that is a frequent reason for consultation in endocrinology. In more than 90% of cases, patients are euthyroid, with benign non-progressive nodules that do not warrant specific treatment. The clinician's objective is to detect malignant thyroid nodules at risk of recurrence and death, toxic nodules responsible for hyperthyroidism or compressive nodules warranting treatment. The diagnosis and treatment of thyroid nodules requires close collaboration between endocrinologists, nuclear medicine physicians and surgeons, but also involves other specialists. Therefore, this consensus statement was established jointly by 3 societies: the French Society of Endocrinology (SFE), French-speaking Association of Endocrine Surgery (AFCE) and French Society of Nuclear Medicine (SFMN); the various working groups included experts from other specialties (pathologists, radiologists, pediatricians, biologists, etc.). This section deals with the surgical management of thyroid nodules.